The Peptide NewsroomPeptide research, industry and supply-chain headlines

Seventh Victorian Liver Case Tied to Counterfeit Retatrutide, But Batch Theory Stays Untested

Three-dimensional structure render: Cryo-EM structure of the retatrutide-bound human GLP-1R-Gs complex
Structure: RCSB PDB entry 8YW3 (CC0 1.0 public domain). Rendering: RCSB PDB.

Doctors in Victoria fear a possible contaminated batch of counterfeit peptides is behind a cluster of hospitalizations for acute liver toxicity, the ABC reports, with the latest patient falling seriously unwell after taking an unapproved product labeled as retatrutide.

Retatrutide is an experimental weight-loss peptide, and peptides are short chains of amino acids that act as signaling agents, telling the body to carry out processes such as hormone release or tissue repair. Eli Lilly holds the sole patent and is running clinical trials, and the Therapeutic Goods Administration says the retatrutide being sold online is not the same product being tested in those trials.

Jaundice within weeks

Seven Victorian patients have now been hospitalized for acute liver toxicity after using a counterfeit of retatrutide, according to the ABC report. Liver transplant specialist Marie Sinclair said the most recent developed severe liver injury after a second dose of the unregulated product.

The speed is the part worth sitting with. Sinclair said affected patients sustained liver injuries within a few weeks of taking the black-market product: "They may become yellow or jaundiced, which is very frightening for patients, and they can become very unwell."

The batch hypothesis, and its evidence

A contaminated batch circulating in Victoria is one possible explanation, Sinclair said, but she stressed there are no testing results to support it and that it is purely a hypothesis at this stage. She has commissioned testing of counterfeit peptides used by the liver failure patients.

TGA chief medical advisor Robyn Langham told the ABC the localized nature of the cases suggested a batch problem, and that the cluster did not appear to be occurring elsewhere in Australia. Langham was careful to say her comments were not the result of an investigation, and that there are no good batches or safe unapproved peptides, which is the more useful framing: a clean batch of an unapproved injectable is still an unapproved injectable.

94,500 products destroyed

The TGA said more than 94,500 unapproved peptide products had been destroyed this year in collaboration with Australian Border Force. Last week, the TGA and New South Wales Police seized more than $120,000 of illicit peptide and anabolic steroid products from premises allegedly linked to social media influencers.

Canberra Health Services confirmed it had detected liver damage from products sold as retatrutide, but would not give numbers due to the low figures involved. Langham said the TGA was particularly concerned that adolescents were buying and injecting products promoted on social media.

What remains unconfirmed

Victoria's Chief Health Officer Caroline McElnay said unapproved peptide products, particularly injected ones, carry significant safety risks including contamination, infection and local tissue damage, and strongly advised against using any of them. Testing is under way, and until it reports, the batch explanation is a hypothesis with seven hospitalizations behind it and no laboratory result yet.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: safety, supply

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

GLP-1 Drugs Linked to Rare Sudden Vision Loss, But Absolute Risk Stays Low

A Rutgers-led study published in Annals of Internal Medicine links GLP-1 drugs including Ozempic and Wegovy to a modest increase in ischemic optic neuropathy, a rare condition that can cause sudden vision loss. The lead author put the increase at roughly three to four additional cases per 10,000 patients over 18 months, and says the data does not establish causation.

Telangana Regulator Warns Online Peptide Buyers Risk Contamination, Serious Reactions and Death

Telangana's drug regulator TG SAFE has warned against buying or self-administering unapproved weight-loss drugs and experimental peptides sold on Telegram and other online platforms, naming BPC-157, GHK-Cu, retatrutide and tesamorelin. The advisory says such products may be contaminated, mislabelled or untested for sterility, and directs doctors not to prescribe them.

FDA Still Silent on Peptide Compounding Vote, But Harm Reports Keep Piling Up

A KFF Health News investigation details adverse event reports tied to BPC-157 while the FDA sits on an advisory panel's July recommendation to ease access to six unapproved peptides. Nevada regulators fined four parties over a 2025 incident in which two women were intubated, but never determined the cause.